Scancell Share Discussion Threads

[inanaco] 26/7/2024 15:38

how funny HVO is now back to the same Share price it was 3 years ago when we took the first bet

and is still overpriced ...

[inanaco] 26/7/2024 15:33

as it is Ivy ......... I bought your shares at 8p and you now won't back HVO with a bet

what does that tell you ..... ?

[inanaco] 26/7/2024 15:31

at least i could answer Knowlesi with a sensible reply ..........


You could not do that

and i backed it up with relevant data


if you go through Bermuda V me on the phase 2/3 adaptive trial

you will find loads of "Bermuda Claims" not backed up with anything ...

left unchallenged with you and Ruck fostering Bermuda the "expert" nonsense

the market would be left with a 3% chance of approval ...

[inanaco] 26/7/2024 15:24

Ivy .....

You told us you sold Viral Vax same as AZN

it turns out after i investigated you sell Live Vax

your another one that has a Job ... they don't understand

didn't you advise that Scancell did not have the skill set to build Covidity ?

your words

just a reminder


""At the levels of deciding how to make a Vax you need real expert scientists so top virologists which Lindy is not.
Not saying she has not got intellect but she is specialist in a different field abd no short cuts tone expertise in a very specific area.""

then Bermuda joined in .... with

""""Also worth noting that Scancell simply don't have a vaccine platform that can be quickly developed and manufactured yet and at the moment speed is of the essence, hence the focus on mRNA vaccines.""""


then Scancell announce they are building a Vaccine with immunobody


i am not making this up ....

[inanaco] 26/7/2024 15:19

put in the data

[ivyspivey] 26/7/2024 15:18

Afternoon CT,
Whether Bermuda has worked in the sector or not is immaterial as we all know he has no personal axe to grind and posts in a balanced way
You choose to believe Inan who again has no science qualification whatsoever or any experience on the pharma industry and has picked up a bit of stuff on the way but is wholly unbalanced in terms of perspective in how he posts and never accepts any other viewpoint due to his totally closed mind

[chilltime] 26/7/2024 15:09

That’s my view Inan, the platforms, or as some describe, separate businesses, offset against each other.

Scib alone going to market is worth a lot, going to phase 2/3 means endorsed and likely a large partner. So on risk there is a great deal of back up compared to the market cap.

Bermuda

You don’t visit often, and try to speak with authority on science related matters here.

Some may think you worked in the sector, just to clarify, as you mentioned in exchanges with Inan on various points (may have got lost in the haze by most)

You have no science related background whatsoever, you have simply invested in this sector for years and picked things up along the way, adding your comments as and when.

I wouldn’t want posters/readers who missed that wrongly thinking you are an expert on the topic, and thus your posts potentially, are fully accepted as likely to be correct.

Perhaps all know you have no history in the sector other than as a retail investor.

[inanaco] 26/7/2024 14:53

He was also on about Risk ... but he clearly had not followed what my NO RISk meant
confusing it with Scancell over 10 years etc

when the bedrock of my NO Risk relates to the value in High Avidity Scib1 in relation to Mcap

which effectively de risked the share

[inanaco] 26/7/2024 14:48

knowlesi was referring to Moditope in effect replicating your thoughts Bermuda

[inanaco] 26/7/2024 14:47

your points are well known ... Scancell wont be the next BioNtech !! etc

[bermudashorts] 26/7/2024 14:26

inanaco,

What point are you trying to make with your c&p of one of my posts from 2019?

[inanaco] 26/7/2024 12:49

so Knowlesi ....

your question is not going to get a simple answer ........

the point is ... It works

and can be made to be effective

if Lindy is correct and is effective as SCIB1 monotherapy

do we have something ...........

maybe you best put the question again to Bermuda ..............

Bermudashorts - 04 Oct 2019 - 10:29:12 - 25678 of 44499
inanaco -

Yes sorry I did miss SCIB2 . So let me ask again:-

Do you really expect Scancell's market cap to jump from £30m to nearly £3.75 billion based on three proof of concept early stage clinical trials? Moreover you think it could be even higher with deals?

[inanaco] 26/7/2024 12:45

Chronic inflammation can increase the risk of cancer in certain parts of the body, such as the colon and cervix. It can cause DNA damage and affect how cells grow and divide, which can lead to tumors and cancer. Chronic inflammation can be caused by:
Infections that don't go away
Abnormal immune reactions to normal tissues
Conditions such as obesity
Diet
Acid reflux
Lifestyle factors, such as sleep quality and stress management
Chronic inflammation can also promote immunosuppression, which can prevent an active immune response from killing mutated oncogenes.

However, inflammation can also be helpful and there are types of inflammation that can help kill tumors. For example, immunotherapies can use inflammatory processes to attack and treat cancer.

[inanaco] 26/7/2024 12:42

whats even more complicated is cancer evolves because of chronic inflammation

there is Good inflammation and Bad .,.............

chronic is BAD

[inanaco] 26/7/2024 12:36

to explain TH1 ....

any t cell can be activated in various states .... and avidity

this is controlled by the vaccine


what we need is TH1 these t cells secrete cytokines that cause inflammation

so powerful that the cytokine could kill you ........... via a "storm" (to much)

that cytokine attracts immune effector cells .... adding potency .....

the cancer supress that ............... that is what you are trying to break to flip to hot cancer

[sci102] 26/7/2024 12:32

Re patents/IP on the other forum. Not impossible legally but impossible in practice. What is possible, is a licensing deal for SCIB1 with the option to additionally license iSCIB1+ according to the final efficacy and addressable population (for example if in the end addresses 80% instead of 100%). It's what scancell should have been aiming for since Sept last year imho.

[marcusl2] 26/7/2024 12:23

Revenue from the company's so-called "growth portfolio" was mainly driven by higher demand for Opdivo, which generated $2.39 billion in sales for the quarter.

So maybe $9.56 billion revenue for a year.

Patent expires 2028.

[inanaco] 26/7/2024 12:22

Hi Knowlesi depends which cancer your targeting .

Scancell has gone for the most aggressive and difficult to treat cancers, the same cancers with PD-1 and doublet approval do not achieve the results of Melanoma with the same checkpoint and doublet checkpoint, the environment is far more difficult, those that did not study the science papers did not pick up on this detail so sold down

so scancell tested with high mutation Hot Cancers .... including Ovarian which has achieved Stable disease using Modi1

MATERIALS AND METHODS
Cell lines and culture
The murine melanoma B16F1 cell line (ATCC-CRL-6323)
and the Lewis lung carcinoma (LLC)/2cell line
(ATCC-CRL-1642) were obtained from the American
Type Culture Collection (ATCC). The murine ovarian
cancer line (ID8) was kindly provided by Dr K Roby at
the University of Kansas Medical Center. The B16F1 cell
line was cultured in RPMI medium 1640 (GIBCO/BRL)
supplemented with 10% FCS, L-glutamine (2mM) and
sodium bicarbonate buffered. The ID8 and LLC/2cell
lines were cultured in DMEM (Sigma, UK) supplemented with 10% FCS. All cell lines used were certified
as mycoplasma-free.

Scancell also has highlighted T regs in the papers when testing human blood to test correctly they had to be deleted

Lindy i suspect was hoping that the TH1 slew would be sufficient to reverse those CD4 T regs from Suppression to effector as those cells have plasticity


""CD4+ T cells, also known as helper T cells, are lymphocytes that help the immune system respond to infections and disease. They can adapt their functions to combat specific pathogens or changing circumstances, a characteristic known as T cell plasticity. This plasticity can provide advantages for the host's immune control and protective immunity""

Modi1 potentially can be upgrade to intravenous SnapVax
Modi1 will work with Modi2 which is more potent against MDSCs cells

""Myeloid-derived suppressor cells (MDSCs) are pathologically activated neutrophils and monocytes with potent immunosuppressive activity.""

CTL-4 will suppress CD4 T regs

cancer is extremely complicated ..... so is the way it suppresses the immune system

which is not just T cells ....

[marcusl2] 26/7/2024 12:04

Moditope and Avidimab may be the most valuable assets that Scancell has.


Modi-2 may be even better.

The Company expects that the combination of Scancell’s Modi-2 with a highly effective platform for inducing T cells (Vaccitech’s SNAPvax™ technology) will lead to a potentially superior therapeutic vaccine candidate.

[marcusl2] 26/7/2024 12:00

If Modi-1 mirrors the course scib has taken with doublet then we are off to the races.

Roll on RCC.

Modi-1 in combination with double checkpoint inhibitors. This approval marks another milestone for Scancell, and the promising efficacy, safety and tolerability study generated from earlier cohorts underscore our belief that our Modi-1 cancer vaccine has the potential to deliver a step change in the treatment of renal and other hard-to-treat cancers."

[chilltime] 26/7/2024 11:04

You get it MT, I get it, but many don’t and wonder why shares open apparently higher or lower on open with no apparent trades or change in the bid offer levels seen the previous day.

I’ve watched various debates on shares. It hasn’t happened here in the last year or two but has twice in a week.

The part to watch during the day is actual prices paid as typically if a buy price heads towards the offer price then it means diminishing MMs at that level and a likely spike up on the offer if buys continue.

[markingtime] 26/7/2024 10:11

I repeat....there is nothing "false" about a price determined by an auction. What is clearly happening is that the buyer has come off the bid and is instead lifting offers, with periodically clearing up more at auction at 14.5p (both at end of day and intraday). The only "false" element of the price is the idea that the bid is at 13.5p....when the traded prices tell you it is really at 14p+. Still.....if anyone is silly enough to hit the bid instead of waiting for an offer to be lifted, that would be very charitable of them.These are all games. Watch the VWAP.